"CPI-0610 Shows Strong Efficacy Signals For Advanced Myelofibrosis" - Silas Inman
The BET inhibitor CPI-0610 demonstrated promising spleen volume responses (SVR) and a meaningful reduction in total symptom score (TSS) as monotherapy and in combination with ruxolitinib (Jakafi) for patients with refractory or intolerant advanced myelofibrosis, according to researchers at the Icahn School of Medicine at Mount Sinai. "CPl-0610 as monotherapy or add-on to ruxolitinib in relapsed/refractory population demonstrated antitumor activity, as evidenced by spleen and symptom improvements, along with improvements in hemoglobin and bone marrow fibrosis," said John Mascarenhas, MD, associate professor of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai. He added, “Among evaluable patients who were transfusion dependent on ruxolitinib, 6 of 14 patients converted to transfusion independence after the addition of CPl-0610 in the study."
— John O. Mascarenhas, MD, Director, The Adult Leukemia Program, Associate Professor, Medicine, Hematology and Medical-Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Additional coverage: Cancer Therapy Advisor; MD Magazine
Mount Sinai Leads Phase 3 Trial in Myelofibrosis Treatment
Mar 19, 2025 View All Press Releases
Mount Sinai Leads Phase 3 Trial in Myelofibrosis Treatment
Mar 19, 2025 View All Press Releases